Cite
HARVARD Citation
Hannelius, U. et al. (2022). IDF21-0113 Design of a precision medicine GAD-alum immunotherapy Phase III clinical trial in Type 1 Diabetes. Diabetes research and clinical practice. p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Hannelius, U. et al. (2022). IDF21-0113 Design of a precision medicine GAD-alum immunotherapy Phase III clinical trial in Type 1 Diabetes. Diabetes research and clinical practice. p. . [Online].